The call for abstracts for the 2024 MTI Regulatory Intelligence and Networking Summit, hosted by Medtech Intelligence, is now open. The Summit, which will be held June 3-5, 2024, Washington, DC, is an intimate and interactive forum designed to help regulatory leaders and their organizations recognize and understand key trends, challenges and solutions impacting the strategy, execution and monitoring of MedTech regulatory process and compliance.
Session and workshops during the 3-day Summit deliver insights addressing a breadth of content—from the ever-changing global landscape of MDR requirements to the latest guidance for integrating transformative technologies and data into your design, manufacturing and quality systems.
Speakers who would like to share their insights, strategies and practices for navigating appropriate regulatory pathways across their respective processes and throughout the product lifecycle, are invited to submit presentations and panel discussion topics by February 15, 2024 here.
We are seeking abstract submissions in the following categories:
- Current regulatory trends
- Digital Transformation in regulatory processes and compliance
- Standards Management
- Collaboration
- Real World Data/Real World Evidence
- Alignment with FDA strategic priorities
- Data management
- Post-market surveillance
- Improving clinical trial diversity
The Summit offers in-person and virtual registration options.
For sponsorship and exhibit inquiries, contact RJ Palermo, Director of Sales.
Related Articles
-
Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.
-
Balwani was found guilty on 10 counts of wire fraud and two counts of conspiracy to commit wire fraud for misleading investors about the financial health of the healthcare startup. He faced up to 20 years in prison for each…
-
Karandeep Badwal, consultant and president of QRA Medical, discusses the change in focus from EU MDD to EU MDR, and how companies will need to adapt to meet new reporting requirements and maintain compliance in the European market.
-
Holmes, who was found guilty in January on three counts of investor fraud and one count of conspiracy to commit fraud related to her blood-testing startup, faced up to 20 years in prison for each guilty count.
